Why are legislatures imposing vaccine mandates now? Meryl Nass, MD
Meryl Nass, MD
… I am a veteran of the vaccine war in the US, and today I feel compelled to speak about what I saw in that war. Legislators were forced to change their votes to revoke vaccine exemptions and rescind the historic right to consent to medical procedures. The vaccine war is a dirty war, in which platitudes about protecting the most vulnerable are invoked by the same pharmaceutical companies that paid $2.7 billion in criminal penalties in the US between 2012 and 2015. The vaccine industry generates enormous profits (estimated 10-40%), benefits from a government-guaranteed market, and receives almost total liability protection. No other industry can rival these benefits. And this industry’s rapacious desire to grow and guarantee its Canadian market is the reason we are here today.
Let me add context to this discussion by noting that in 2014, the NY Times said it cost $2200 to fully vaccinate one child. At that price, it cost $163 billion dollars to fully vaccinate every US child. May I apologize at the outset for using mostly US data? I provide Canadian and New Brunswick information when available.
On the other hand, the industry does not want to shoulder the considerable expense of developing, testing and licensing new vaccines–over 100 of which are in development–without a government guarantee that they will be purchased.Vaccines are being developed for everything from acne to cancers.
Vaccine mandates guarantee a vaccine market, now and in the future. Mandates put in place today will enforce the uptake of vaccines on the currently required list, plus other vaccines yet to be added.
Industry Challenges
In 2019, the vaccine industry faces threatening legal challenges.
Facing these challenges, in 2019 the vaccine industry seized its opportunity from a prolonged US measles outbreak. A flawlessly conducted PR campaign conducted for the industry helped ram through legislation for enforced vaccine mandates in the US, and now the industry is repeating the strategy in Canada.
Is New Brunswick prepared for a significant reduction in the number of children who attend public school?
You have been assured that “Vaccines are safe and effective.”
It has a reassuring ring, but conveys nothing. In fact, each vaccine is very different from every other. Generally, we know something (but not enough) about the benefit, but only a little about the harms of different vaccines. According to the Institute of Medicine, “The process of anticipating, detecting, and quantifying the risks of rare adverse events following immunization presents an enormous challenge.” Like drugs, each is appropriately used when the benefit outweighs the risk. Because vaccines are given to healthy people to prevent disease, they should be even safer than drugs.
The initial effectiveness of the different childhood vaccines ranges from about 40% to 93%. Immunity then wanes over time.
There is a big problem at the heart of vaccine safety assessment: adverse event information is cloaked in secrecy, withheld from physicians and the public by
public health agencies. Undesirable results are massaged or falsified until they appear acceptable. Because this is hard to believe, I will give you 3 important examples of CDC’s data manipulation.
Thomas Verstraeten was a young physician on a CDC fellowship who in 1999 studied the statistical relationship between cumulative amounts of thimerosal (mercury) infants received from vaccines and neurological illnesses. His results–including that children exposed to the highest levels of mercury from vaccines after birth had 7 times the level of autism as children not exposed–were so disturbing that CDC convened a private meeting of vaccine experts to discuss and manage them. No reporters or members of the public were permitted, but a copy of the meeting transcript was leaked. (I have provided you with an unpublished abstract obtained by FOIA showing some of Verstraeten’s data before it was massaged to remove the effect of mercury. His published 2003 paper says, “No consistent significant associations were found between thimerosal (mercury) containing vaccines and neurodevelopmental outcomes.” I also gave you a letter from physician Congressman Bill Weldon to Dr. Julie Gerberding, director of the CDC about this data manipulation.The issue is unresolved. Merck was later found to have misled the public about when it removed thimerosal from infant vaccines.
Despite strong evidence of scientific misconduct in these 3 CDC cases, the papers published in top medical journals with these manipulated data have never been retracted from the medical literature. Instead, they provide foundational support for the safety of the MMR vaccine and of mercury in vaccines. The fraudulent papers pollute the medical literature, making it impossible to discern the true adverse effects of vaccines.
It is very difficult to link an adverse reaction to a vaccination unless it occurs soon afterward. In general, late adverse reactions are only identified as caused by vaccines if they occur many times more often than expected.
The National Academy of Sciences (NAS) was chartered by Congress in 1863 to provide expert advice to government. Congress requested the National Academy’s Institute of Medicine (IOM) to conduct a series of vaccine safety studies to inform vaccine policy.
“While few health problems are clearly associated with vaccines and some putative associations can be rejected based on evidence, in the majority of cases evidence was inadequate to accept or to reject a causal relationship… Confidence in vaccine safety requires more than surveillance and reporting in real time. In light of the paucity of strong conclusions about possible vaccine side effects, continued and selective investment in epidemiologic and other investigations into the risks of immunization will be necessary…About the best one can do is to estimate, based on the evidence, the probability that the frequency of an adverse event is less than a specified, low level. This may be enough for the physician who weighs the public health and personal health benefit against a very low risk, but not enough to satisfy a wary parent.
Continued, candid, and open communication is also an essential ingredient to a successful vaccine safety regime. This means more than the experts explaining the benefits and risks to parents and families. It means listening carefully to the anxieties and doubts, staying true to the strength of evidence without exaggeration or misrepresentation, and reporting fully and fairly on scientifically sound investigations into possible adverse events.” [Highlight added]
Knowledge of the adverse effects due to single vaccines, combinations of vaccines, or the number of vaccines remains murky.
Canadian physicians examined the health of babies after their 12 and 18 month vaccinations. They found an excess emergency room visit for one in every 168 babies vaccinated at 12 months with the MMR vaccine, occurring between one and two weeks later. They concluded,
1300 cases of narcolepsy were caused by the 2009 swine flu Pandemrix vaccine.
This particular side effect was able to be linked to the vaccine because millions of people were vaccinated simultaneously, the narcolepsy that developed was severe and required intense medical attention, the rate of narcolepsy was 10-16 times higher than expected, and vaccine oversight had been increased to evaluate new pandemic vaccines. Canadians received a virtually identical vaccine (Arepanrix) but it was manufactured in a different facility, and by chance alone the Canadian version did not cause narcolepsy.
Is New Brunswick undergoing a crisis of vaccine-preventable disease?
The answer is no. And if there was a crisis, Bill 39 would not wait to go into effect until 2021.
Families that have experienced a serious vaccine reaction are right to be concerned about additional vaccinations and the safety of sibling vaccination, for their family is probably at higher than average risk of a reaction. What goes unreported is that many unvaccinated children are themselves a vulnerable group, and should not be vaccinated. However, there are no existing standards for doctors to use to determine the risk of vaccination to most children. So medical exemptions must be improvised, and are generally hard to come by.
Herd Immunity is undermined by high rates of vaccine failures
The Quebec measles epidemic I mentioned demonstrates that even a vaccination rate over 95% didn’t prevent a large measles outbreak. Herd immunity rates are based on statistical modelling, and are only projections. The reason that 50% of measles cases occurred in vaccinated children is primary or secondary vaccine failure. Primary vaccine failure means the vaccine never produced immunity, while secondary failure means the immunity was lost over time.
For most vaccines, primary and secondary failures go unnoticed, because children are not being exposed to most of these infections. The infections children do get exposed to are pertussis and influenza, and then vaccine failure is obvious–because most cases of pertussis and many of influenza occur in fully vaccinated children.
Do unvaccinated children put immunocompromised children at risk?
The fact is that immunocompromised children are not dying from vaccine preventable diseases, and few are getting them, with the exceptions of influenza, pertussis and varicella–because vaccines for these 3 infections provide limited immunity.
Fewer than one American dies yearly from measles, mumps, rubella, polio, or diphtheria. On average, one Canadian dies from whooping cough (pertussis). Ten Canadian children die from influenza. One American child dies yearly from varicella (chickenpox).
You are looking at 11 child deaths per year in Canada. Would vaccinating every child fully against whooping cough, varicella and influenza prevent these deaths? Remember, most whooping cough and varicella patients are fully vaccinated. And while the immunity generated in young children from flu shots varies yearly, it is usually less than 50%.
Herd immunity cannot be achieved for whooping cough or influenza because neither vaccine is adequate. Pertussis vaccine immunity wanes so quickly that little protection is left after 3-4 years. Transmission to others can occur before you realize you have influenza or pertussis.
Even if 100% of Canadians were vaccinated, these diseases would continue to circulate within the vaccinated and the unvaccinated population.
Varicella cannot be eradicated both because the vaccine is not optimal (85% efficacy), waning occurs, and because the virus stays in your body permanently after vaccination or infection. Most immunocompromised children who develop varicella infections do so from virus already resident in their bodies.
The claim that vaccine exemptions put immunocompromised children at risk was invented by PR firms, with no evidence behind it.
While vaccination rates reported in New Brunswick are low, non-medical exemption rates are also low: 2%. The likeliest explanation for lack of epidemics despite low recorded vaccination rates is inadequate recordkeeping.
In Maine, with similar demographics, vaccination rates for each of the required vaccines is about 95%. Exemption rates vary by vaccine. Only 1% of US children receive no vaccines. Up to 25% receive some, but not every available vaccine.
Should we be concerned about vaccine quality and origin?
Translation: vaccines contain unknown substances, unknown even to the FDA and Public Health Agency of Canada. This makes them challenging to regulate. The FDA relies on vaccine manufacturers to provide accurate data about each step in the manufacturing process. When a problem occurs during manufacturing, the FDA expects to be told and expects the manufacturer to recall affected lots of vaccine when necessary. I have provided you information on 5 vaccine recalls or other issues in Canada since 2012.
The FDA usually redacts information about the locations where vaccine ingredients are manufactured. I am under the impression that at present, US vaccine products are made in Europe and North America.
Large multinational pharmaceutical companies, such as Sanofi, which has vaccine manufacturing facilities in both India and China, are manufacturing vaccines in underdeveloped nations. China and India each have over 20 vaccine manufacturers. It is probably only a matter of time before vaccines manufactured in countries known for inadequate government monitoring of pharmaceuticals are being used in Canada and the US.
“In July, China experienced its “worst public health crisis in years” as stated by South China Morning Post. Chinese vaccine maker Changsheng Biotechnology was found to have fabricated production and inspection records and to have arbitrarily changed process parameters and equipment during its production of freeze-dried human rabies vaccines. Furthermore, substandard diphtheria, pertussis, and tetanus (DPT) vaccines produced by Changsheng Biotechnology were administered to 215,184 Chinese children; and 400,520 substandard DPT vaccines produced by Wuhan Institute of Biological Products were sold in Hebei and Chongqing. On July 25, China’s drug regulator launched an investigation into all vaccine producers across the country. Fifteen people from Changsheng Biotechnology, including the chairman, have been detained by Chinese authorities.
This latest vaccine scandal follows on from a series of fake and substandard food and drugs issues in China. As a result, many parents have lost faith in the vaccine system.”
Influenza, and the Fluadvaccine
Influenza is a disease that affects from 3-20% of the population yearly. There were 6515 reported influenza deaths in the US in 2017, during the decade’s worst outbreak. CDC uses mathematical models to estimate influenza deaths, and the estimates include deaths from other heart and lung conditions, in people who had influenza. These estimates usually range from 30-50,000 deaths yearly, related to influenza. Ninety percent of influenza deaths occur in those over age 65. While most people over 65 receive annual flu vaccines in the US, this age group is less likely to develop immunity from the vaccine, compared to younger people. Overall, flu vaccine effectiveness averages about 40%, according to the CDC.
Each year, influenza vaccines are newly made to contain the dominant strains predicted for that season. Because of the need to make different products each year, and make them rapidly available for each flu season, they are not tested to the same extent as other vaccines. Clinical trials to test for safety are not required for yearly changes to flu vaccines. Effectiveness trials are impossible to do prior to mass use. Yearly flu vaccines are “grandfathered in,” although they are checked for manufacturing defects.
Possible reasons this occurred include the revolving door between vaccine manufacturers and regulators, the abbreviated safety testing of flu vaccines, and the liability protection given to manufacturers by governments. The episode provides a warning that regulators’ first priority may not always be the public’s welfare.
The response of elders to flu vaccines is particularly poor. Two strategies are being tried to enhance vaccine immunity in this age group. The first involves using higher concentrations of antigens in the vaccines. The second involves using novel adjuvants, which are substances that provide increased stimulation to the immune system. Potentially this can improve immunity, but it might increase inflammation and autoimmune illnesses.
The Fluad vaccine is the only influenza vaccine in Canada and the US to contain a novel, immune-boosting adjuvant. The adjuvant is called MF59 C1. Originally produced by an Italian company, the adjuvant-containing flu vaccine was licensed for elders only, in Italy, in 1997. It was not licensed in the US until 2015, for elders only, presumably because they were less likely to experience complications from the vaccine’s additional immune stimulation. I have been unable to find unbiased literature on the MF59 adjuvant or the Fluad vaccine, as all the research has been sponsored by its manufacturers (Sclavo, then Chiron, then Novartis, and now Sequirus).
Fluad was licensed for elders in Canada in 2011. The government of Ontario’s fact sheet on the vaccine makes clear that by 2016 it was still not known whether the excess immune stimulation it provides actually improved protection against the flu:
“How well does the Fluad® vaccine protect against influenza? Influenza vaccines may decrease hospitalizations and deaths among elderly individuals. According to the product monograph, Fluad® produces a higher immune response in elderly individuals when compared to other influenza vaccines without an adjuvant. The higher immune response may indicate that Fluad® works better than unadjuvanted vaccines, although this is not known for certain.”
Nor is it known how safe the adjuvanted vaccine is. It causes about 15% more local reactions than nonadjuvanted flu vaccines, but we don’t know if it causes more serious, or later onset, adverse reactions.
“Severe reactions are rare, but several of the reviewed studies were too small to detect clinically significant but rare adverse events. In particular, the safety information is limited for ATIV (adjuvanted trivalent influenza vaccines) in children with immunodeficiencies and other chronic illnesses…
There are insufficient data to assess whether ATIV (adjuvanted flu vaccine) is more effective than UTIV (unadjuvanted flu vaccine) or LAIV (live attenuated flu vaccine) in practice or to make an informed risk-benefit analysis.”
The reviewers also noted that the European Medicines Agency (EMA) failed to license the vaccine for European children in 2012. The EMA report found a number of problems with the single pivotal clinical trial of Fluad in children. Furthermore, the EMA report states, “The current application, although related to a product developed more than 15 years ago and authorized for use in the elderly, includes only one study addressing clinical vaccine efficacy.” The report concludes, “The overall benefit-risk balance of Fluad Paediatric is negative.”
Despite a) the lack of evidence of benefit, b) limited and c) unreliable safety information, d) rejection in Europe, and e) no evidence of any other country using it for children, f) let alone use in infants–in 2015 the Public Health Agency of Canada (PHAC) licensed Fluad pediatric for use in infants and babies aged 6 months to 2 years.
It seems that Canada’s youngest children have been selected to serve as the unwitting guinea pigs in a massive immune stimulation experiment of this novel-adjuvanted vaccine.
What were the members of the Public Health Advisory Committee thinking?
Will Canadian children serve as experimental subjects, without their parents’ knowledge, for additional vaccines selected for them by their public health agency?
Public health officials use the mass media, medical professionals and the levers of government to encourage, exhort and cajole vaccinations. Their conduct with the Fluad pediatric vaccine has shown they must not be given the power to compel.